Navigation Links
Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
Date:9/24/2009

ction of our new production facility which greatly improves our capacity to support growth during fiscal 2010 and beyond. While the past year was challenging for the global marketplace, we took decisive corporate actions which included issuing a cash dividend and buying back stock to reward our loyal shareholders."

Year Ending June 30, 2009 Financial Results

For the fiscal year ended June 30, 2009, revenues increased 28.2% to $42.9 million from $33.5 million reported for the prior year period. Expanded sales efforts helped create strong demand for the Company's branded and generic drugs including the introduction of 9 new drugs. Ginkgo Mihuan, one of Tianyin's flagship products, contributed approximately $11.6 million or 27.1% to total revenues for the fiscal year 2009, representing 28% year-over-year growth. Revenues generated from the Arpu Shuangxin Oral Liquid were $10.4 million, or 24.2% of total revenues, a 54.3% increase from fiscal 2008. Tianyin's top 5 selling products generated revenue of $29.3 million and represented 68.3% of total revenue.

Cost of goods sold for fiscal year 2009 was approximately $21.5 million, yielding a gross profit of $21.4 million and gross margins of 49.8%, compared to $14.7 million in gross profit and a gross margin of 43.8% for fiscal year of 2008. The 600 basis point improvement in gross margins was primarily attributable to the growth in revenue, product mix optimization, enhanced cost control and focus on higher margin products in the Company's portfolio such as Ginkgo Mihuan Oral Liquid and Arpu Shuangxin Oral Liquid.

Operating expenses for fiscal year 2009 were $11.7 million, up 64.5% compared to the same period in 2008. Selling, general and administration expenses for the period increased to approximately $7.8 million from $4.7 million. The increase was primarily due to enhanced marketing efforts including increased sales payrolls and dire
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
3. Tianyin Pharmaceutical Appoints Three New Independent Board Members
4. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
5. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
6. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
7. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
8. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
9. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
10. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
11. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... France (PRWEB) September 23, 2014 ... of laboratory personnel since 1968 and Burdinola, supplier of ... of a new filtered fume hood. , ... laboratory fume hood, Burdinola will now offer an innovative ... a wide range of chemicals, best-in-class detection technology, and ...
(Date:9/23/2014)... , Sept. 23, 2014 Research ... "Proteomics Markets for Research and IVD Applications ... report to their offering. ... proteomics applications, both in their research use and ... including the study of the structure and function ...
(Date:9/23/2014)... 2014 For the fifth time since 2006, ... of the fastest-growing companies. , “We’re so proud that ... by Inc. Magazine,” ExakTime CEO Tony Pappas said. , ExakTime ... a three-year growth rate of 61 percent from 2010 to ... more than 40 percent. , Pappas cited strong performance in ...
(Date:9/23/2014)... Jose, California (PRWEB) September 23, 2014 ... Agricultural biotechnology is gaining steady popularity the world ... plant breeding techniques. Growth in the marketplace is ... Modified (GM) crops in developing countries. Several sub-Saharan ... of under-nourished population, have already implemented genetically engineered ...
Breaking Biology Technology:Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 3Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 4ExakTime Makes Inc. 5000 List for the Fifth Time 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... a material in which an electric field can control the ... effect discovered by the Rutgers group can be extended to ... bits in ultra high-density data storage. The research appears in ... The researchers found the effect by studying the magnetic properties ...
... ROCKVILLE, Md., Aug. 22 A research team co-led by ... Institute for Genome Sciences (IGS), University of Maryland School of ... bean ( Ricinus communis ) genome in Nature Biotechnology ... IGS were co-lead authors on the paper describing the 4.5X ...
... Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using... -- BRUSSELS, August 19, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 2Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 3Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 2Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 3Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 4Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 5Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 6Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 7
(Date:9/23/2014)... has secured $21 million in a Series C Financing. ... Company,s cancer immunotherapy pipeline and advance its lead programs ... round, with participation from Majuven and all existing major ... Venture Capital. , Eureka is engaged in the ... the functions of a T cell receptor, a key ...
(Date:9/23/2014)... majority of drugs used to treat asthma today are the ... are urgently needed to treat this chronic respiratory disease, which ... to wheeze, cough, and find it difficult at best to ... is tough: asthma is a patient-specific disease, so what works ... animal models traditionally used to test new drug candidates often ...
(Date:9/23/2014)... infant chimpanzees from their mothers are well documented, little ... of early life experience. In a year-long study, scientists ... that those who were removed from their mothers early ... performers are likely to show behavioral and social deficiencies ... in the open-access journal PeerJ , was led ...
Breaking Biology News(10 mins):Airway muscle-on-a-chip mimics asthma 2Airway muscle-on-a-chip mimics asthma 3Chimpanzees raised as pets or performers suffer long-term effects on their behavior 2
... days after Hurricane Sandy hit, NJIT Professor Michel Boufadel was ... impact of the storm on the New Jersey shoreline. ... take a team of eight researchers to the beaches of ... five students is still fanning out over the shoreline ...
... in Spanish . U.S. Department of ... against sand flies, which are major pests in Afghanistan, Africa ... vectors of Leishmania parasites that cause leishmaniasis, a devastating disease ... who are bitten by infected sand flies do not know ...
... way foot and mouth disease will be controlled in ... emerging poultry viruses, Two new research projects have ... most devastating livestock and poultry viruses. The two projects, ... (BBSRC), aim to provide novel solutions to combatting the ...
Cached Biology News:NJIT civil engineer receives NSF grant to study storm's impact on Jersey Shore 2Protecting US troops against sand flies 2£12 million funding to tackle devastating livestock and poultry viruses 2£12 million funding to tackle devastating livestock and poultry viruses 3£12 million funding to tackle devastating livestock and poultry viruses 4
Several Pichia pastoris strains are available to allow you to optimize expression and recovery of your protein of interest. Table 1 provides information to help you choose the appropriate strain....
Standard 2" or 3" Plastic can be ordered with 81 or 100 cell dividers. Mini 2" Plastics Boxes come standard with 25 cell dividers. Plastic boxes can also be ordered with corresponding freezer racks...
Request Info...
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
Biology Products: